Table 2 Major findings reported for the use of CX-4945 and CIGB-300 in cell and in vivo
From: Protein kinase CK2: a potential therapeutic target for diverse human diseases
CIGB-300 | CX-4945 | |
|---|---|---|
In vitro studies | Antiproliferative effect and apoptosis induction in different cancer cell lines318,319,320,321 Angiogenesis inhibition323 Adhesion, migration and invasion reduction in different cancer cell lines56,321 | Antiproliferative effect and apoptosis induction in different cancer cell lines43,98,100,319,324,325,326,327,328,329,330 Angiogenesis inhibition328 Adhesion, migration and invasion reduction in different cancer cell lines77,333,334 Inhibition of cell differentiation267,268,335,336 Overcoming cancer cells chemoresistance37,42 Suppression of DNA damage repair mechanism337 Intracellular Ca++ dynamics regulation338 Splicing regulation339 Reduction of pro-inflammatory cytokines release106,163 Stimulation of insulin release283 Regulation of anion channels activity230,231 Potential anti-COVID-19 treatment199 |
In vivo studies | Anti-tumor effect in murine models96,324,327,328,329,330,331,332 | |
Human studies | Tumor reduction in women affected by cervical cancer322 Cancer clinical trialsa: NCT01639625, NCT01639638 | Cancer clinical trialsb: NCT01199718, NCT00891280, NCT03897036, NCT02128282, NCT03904862, NCT03571438 COVID-19 clinical trialsb: NCT04668209, NCT04663737 |
